Glial cell line-derived neurotrophic factor receptor alpha 1-Rearranged during transfection signaling complex (GFRα1-RET)

The GFRα1-RET signaling complex is a multicomponent receptor system primarily activated by the Glial cell line-derived neurotrophic factor (GDNF) (UniProt: P07949, P56159). In this complex, GFRα1 acts as a high-affinity ligand-binding co-receptor that lacks a transmembrane signaling domain, instead anchoring to the plasma membrane via a glycosylphosphatidylinositol (GPI) link (PubMed: 9130617). Upon GDNF binding, GFRα1 recruits the RET receptor tyrosine kinase, inducing its homodimerization and subsequent autophosphorylation of intracellular tyrosine residues (Nature: 10.1038/381791a0). This activation triggers vital downstream signaling cascades, including the RAS/MAPK, PI3K/Akt, and PLCγ pathways, which are essential for the development of the enteric nervous system and renal morphogenesis (Cell: 10.1016/S0092-8674(00)81298-5). Dysregulation of this complex, often through RET gene fusions or activating mutations, is a primary driver in various malignancies such as medullary thyroid cancer and certain lung adenocarcinomas (Journal of Clinical Oncology: 10.1200/JCO.2018.78.2433). Consequently, the RET kinase component of the complex has become a significant therapeutic target for highly selective small-molecule inhibitors like selpercatinib and pralsetinib (FDA: Retevmo, Gavreto). Beyond oncology, the complex is also investigated for its role in neuroprotection, particularly in Parkinson's disease, where GDNF-mediated activation is sought to support dopaminergic neuron survival (PubMed: 10851174). Therapeutic strategies targeting this complex must account for potential resistance mechanisms, such as gatekeeper mutations in the RET kinase domain that can hinder drug binding (Nature Reviews Clinical Oncology: 10.1038/s41571-018-0006-9).

Other names

GDNF receptor complexGFRalpha1-RET complexRET-GFRA1 signaling unitGDNF-GFRalpha1-RET complex

Small molecule inhibitors bind to the ATP-binding pocket of the RET kinase domain within the complex, preventing autophosphorylation and subsequent activation of downstream signaling pathways such as MAPK/ERK and PI3K/Akt (PubMed: 32983361).